Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared...
Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC / cancer, Huaqiu Shi, Liming Zhu, Ling Zhang, Lung cancer, NSCLC, Stephen Liu/X Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC Stephen Liu, Director...
A multinational research team led by Dr. William J. McDaid, Dr. Colin R. Lindsay, and Professor Angeliki Malliri at The University of Manchester and The Christie NHS Foundation Trust reports that KRAS G13C-mutant non-small cell lung cancer (NSCLC)-a previously untargetable...
NANJING, China, July 9, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase...
Genentech’s next-generation KRAS G12C inhibitor, divarasib, demonstrated superior survival outcomes over sotorasib and adagrasib in a head-to-head study, maintaining a manageable and consistent safety profile Topline data were announced from a head-to-head phase 3 trial evaluating divarasib vs first generation...
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation PR Newswire NANJING, China, July 9, 2026 NANJING, China, July 9,...
This is a paid press release. Contact the press release distributor directly with any inquiries. InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC)...
Breakthrough research in Manchester unveils new drug combo for rare KRAS-mutated lung cancer, boosting patient outcomes globally. Study in Cancer Discovery targets NSCLC, a major cause of cancer deaths New Drug Combo for KRAS Lung Cancer: Hope for Patients New...
Genentech’s next-generation KRAS G12C inhibitor, divarasib, demonstrated superior survival outcomes over sotorasib and adagrasib in a head-to-head study, maintaining a manageable and consistent safety profile Topline data were announced from a head-to-head phase 3 trial evaluating divarasib vs first generation...
